Heat Biologics Inc  

(Public, NASDAQ:HTBX)   Watch this stock  
Find more results for HTBX
0.385
+0.011 (2.94%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.35 - 0.38
52 week 0.30 - 1.25
Open 0.37
Vol / Avg. 383,786.00/507,859.00
Mkt cap 14.18M
P/E     -
Div/yield     -
EPS -0.42
Shares 35.79M
Beta 0.69
Inst. own 11%
Nov 13, 2017
Q3 2017 Heat Biologics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -531.88% -3797.80%
Operating margin -539.82% -3842.44%
EBITD margin - -3803.78%
Return on average assets -63.20% -117.46%
Return on average equity -101.62% -195.75%
Employees 19 -
CDP Score - -

Address

801 Capitola Dr
DURHAM, NC 27713-4382
United States - Map
+1-919-2407133 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Officers and directors

Jeffrey Alan Wolf J.D. Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Timothy J. Creech Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Jeff Tobin Hutchins Ph.D. Chief Operating Officer, Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Ann A. Rosar Vice President - Finance, Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Anil K. Goyal Ph.D. Vice President - Business Development
Age: 51
Bio & Compensation  - Reuters
John K. A. Prendergast Ph.D. Director
Age: 63
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 52
Bio & Compensation  - Reuters
Michael Kharitonov Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters
John P. Monahan Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Edward B. Smith III Independent Director
Age: 40
Bio & Compensation  - Reuters